Seeking Alpha
22 Sept 2026, 18:50 UTC · 7h ago
Verdict
Headline leans bullish. We score CNDL +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 0 new · 3 priced in
Aglatimagene reduced disease recurrence risk by 30% in a pivotal phase 3 trial for localized prostate cancer.
Priced inanalysis of existing phase 3 success
More positive than 99% of claims this week
Candel Therapeutics intends to file a Biologics License Application (BLA) for aglatimagene in Q4 2026.
Priced in
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
So whatThe filing timeline suggests a potential commercial launch window in 2027 following FDA review.
More positive than 92% of claims this week
The company is advancing aglatimagene in metastatic NSCLC through the AURORA trial.
Priced inanalysis of existing phase 3 success
More positive than 77% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Upgraded to Strong Buy following phase 3 success in prostate cancer and a positive primary endpoint result.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
CNDL hasn't traded since this ran. Last close $0.0001 (Sep 21); the reaction starts at the next open.
CNDL chart →
